Kaplan-Meier survival curve for 306 pancreatic ductal adenocarcinoma patients.

<p>Kaplan-Meier survival curve for 306 pancreatic ductal adenocarcinoma patients.</p

Serial H&E (A,C) and BAP1 IHC (B, D) stained sections of pancreatic ductal adenocarcinomas which demonstrate positive immunohistochemical staining for BAP1.

<p>All the neoplastic and non-neoplastic cell demonstrate diffuse strong nuclear staining (Original magnification A,B 100x, C,D 400x).</p

Haematoxylin & eosin (A, C) and BAP1 immunohistochemistry (B, D) stained sections from the sole pancreatic ductal adenocarcinoma patient who expressed loss of nuclear BAP1.

<p>In this case, the exocrine cells (solid arrows) clearly lacked the brown BAP1 staining, and the non-neoplastic endothelial cells serve as the internal positive controls (hollow arrows). Magnifications: A, B 100x; C, D 400x.</p

Clinical and pathological characteristics of 306 pancreatic adenocarcinoma patients.

<p>Clinical and pathological characteristics of 306 pancreatic adenocarcinoma patients.</p

Clinical and pathological features of 1109 consecutive patients with CRC.

<p>Clinical and pathological features of 1109 consecutive patients with CRC.</p

Overall survival of patients with CRC stratified by MMR and BRAF status (Cox regression modelling).

<p>Overall survival of patients with CRC stratified by MMR and BRAF status (Cox regression modelling).</p